SymBio Pharmaceuticals Limited (TYO:4582)
Japan
· Delayed Price · Currency is JPY 115.00
-6.00 (-4.96%)
Mar 9, 2026, 3:30 PM JST
SymBio Pharmaceuticals Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,308 | 2,452 | 5,589 | 10,008 | 8,257 | Upgrade
|
| Revenue | 1,308 | 2,452 | 5,589 | 10,008 | 8,257 | Upgrade
|
| Revenue Growth (YoY) | -46.67% | -56.13% | -44.16% | 21.21% | 176.42% | Upgrade
|
| Cost of Revenue | 360.31 | 579 | 1,179 | 2,408 | 2,452 | Upgrade
|
| Gross Profit | 947.34 | 1,873 | 4,410 | 7,600 | 5,804 | Upgrade
|
| Selling, General & Admin | 2,091 | 2,371 | 2,584 | 3,082 | 3,048 | Upgrade
|
| Research & Development | 3,297 | 3,379 | 2,638 | 2,554 | 1,736 | Upgrade
|
| Other Operating Expenses | - | - | - | - | 4.34 | Upgrade
|
| Operating Expenses | 5,388 | 5,750 | 5,222 | 5,636 | 4,788 | Upgrade
|
| Operating Income | -4,441 | -3,877 | -812 | 1,964 | 1,016 | Upgrade
|
| Interest Expense | -149.45 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 4.2 | 32 | 11 | - | 2.7 | Upgrade
|
| Currency Exchange Gain (Loss) | -64.96 | 172 | 117 | 136 | -20.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -21.37 | -17 | -45 | -100 | 2.61 | Upgrade
|
| EBT Excluding Unusual Items | -4,672 | -3,690 | -729 | 2,000 | 1,001 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -7 | - | - | Upgrade
|
| Asset Writedown | -109.27 | -131 | -560 | - | - | Upgrade
|
| Other Unusual Items | 8.54 | 14 | 101 | 106 | 0.2 | Upgrade
|
| Pretax Income | -4,749 | -3,807 | -1,195 | 2,106 | 1,001 | Upgrade
|
| Income Tax Expense | 27.57 | 26 | 767 | 927 | -1,031 | Upgrade
|
| Net Income | -4,776 | -3,833 | -1,962 | 1,179 | 2,032 | Upgrade
|
| Net Income to Common | -4,776 | -3,833 | -1,962 | 1,179 | 2,032 | Upgrade
|
| Net Income Growth | - | - | - | -41.98% | - | Upgrade
|
| Shares Outstanding (Basic) | 50 | 45 | 40 | 39 | 38 | Upgrade
|
| Shares Outstanding (Diluted) | 50 | 45 | 40 | 40 | 39 | Upgrade
|
| Shares Change (YoY) | 11.34% | 13.02% | 0.75% | 1.97% | 17.88% | Upgrade
|
| EPS (Basic) | -95.12 | -84.99 | -49.17 | 30.19 | 53.04 | Upgrade
|
| EPS (Diluted) | -95.12 | -84.99 | -49.17 | 29.77 | 52.32 | Upgrade
|
| EPS Growth | - | - | - | -43.10% | - | Upgrade
|
| Free Cash Flow | -4,576 | -3,435 | -398 | 1,612 | 114.59 | Upgrade
|
| Free Cash Flow Per Share | -91.13 | -76.17 | -9.97 | 40.70 | 2.95 | Upgrade
|
| Gross Margin | 72.45% | 76.39% | 78.91% | 75.94% | 70.30% | Upgrade
|
| Operating Margin | -339.59% | -158.12% | -14.53% | 19.62% | 12.31% | Upgrade
|
| Profit Margin | -365.25% | -156.32% | -35.10% | 11.78% | 24.61% | Upgrade
|
| Free Cash Flow Margin | -349.91% | -140.09% | -7.12% | 16.11% | 1.39% | Upgrade
|
| EBITDA | - | -3,779 | -714 | 2,063 | 1,110 | Upgrade
|
| EBITDA Margin | - | -154.12% | -12.78% | 20.61% | 13.44% | Upgrade
|
| D&A For EBITDA | - | 98 | 98 | 99 | 93.96 | Upgrade
|
| EBIT | -4,441 | -3,877 | -812 | 1,964 | 1,016 | Upgrade
|
| EBIT Margin | - | -158.12% | -14.53% | 19.62% | 12.31% | Upgrade
|
| Effective Tax Rate | - | - | - | 44.02% | - | Upgrade
|
| Revenue as Reported | - | - | - | - | 8,257 | Upgrade
|
| Advertising Expenses | - | 692 | 937 | 1,481 | 1,643 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.